Abstract: Gene panels, microarrays and biomarker panels relating to genes and gene products associated with age-related oxidative damage to skin, and transcriptional profiling-based methods for identification and evaluation of cosmetic agents for prevention, reversal, or reduction of oxidative damage to skin. Cosmetic agents and compositions comprising the cosmetic agents, capable of inducing nrf2-mediated activation of the antioxidant response element to increase expression of Phase 2 enzymes, methods for restoring optimal redox status to skin employing the agents, and methods for identifying and evaluating cosmetic agents acting via the nrf2-mediated mechanism.

Abstract: Personal care compositions comprising a dipeptide and methods of using such compositions to treat the condition of keratinous tissue. The C terminal amino acid of said dipeptide is threonine. The personal care composition can be applied topically, ingested orally, injected, or used as part of a combined treatment regimen.

Abstract: A skin-care composition may comprise a dill extract, a safe and effective amount of a peptide, a safe and effective amount of a hydrating skin active, and a dermatologically acceptable carrier. The skin-care composition may further comprise a safe and effective amount of an acute skin-care active. Further, a method of producing a chronic skin-firming benefit and, optionally, an acute skin-tightening sensation, said method comprising the step of topically applying to the skin of a mammal in need of such treatment, a safe and effective amount of the skin-care composition.

Abstract: Personal care compositions comprising an active component, use of such compositions, and methods of marketing such compositions. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.

Abstract: Personal care composition comprising at least one extract selected from the group consisting of extracts of Terminalia bellerica, Butea monosperma, Mallotus philippinensis, Anogeissus latifolia, Innula racemosa, Ficus benghalensis, Nerium indicum, Psoralea corylifolia, Acacia catechu, Abies pindrow, Cedrus deodara, Emblica officinalis, Moringa oleifera, Glycyrrhiza glabra, and mixtures thereof, and a dermatologically acceptable carrier. Additionally or alternatively, the composition may comprise 2-hexyldecanol.

Abstract: Personal care compositions comprising a dipeptide; one or more of the following: a pentapeptide, a second dipeptide, a vitamin B3 compound, a hexamindine compound, and/or a sugar amine; and a dermatologically acceptable carrier. Methods of using such compositions to treat the condition of keratinous tissue. In certain embodiments, the C terminal amino acid of said dipeptide is threonine.

Abstract: Personal care compositions comprising an active component, use of such compositions, and methods of marketing such compositions. In one embodiment, the active component comprises pear seed extract. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.

Abstract: A personal care composition may comprise a member selected from a group consisting of kinetin, zeatin, and combinations thereof; niacinamide; and a dermatologically-acceptable carrier. A personal care composition may comprise an N-acyl amino acid compound, a skin care active, a member selected from a group consisting of kinetin, zeatin, and combinations thereof, and a dermatologically-acceptable carrier. A personal care composition may comprise a hexamidine compound, a skin care active, a member selected from a group consisting of kinetin, zeatin, and combinations thereof, and a dermatologically acceptable carrier.

Abstract: Methods for identifying materials that can help regulate the condition of mammalian keratinous tissue (e.g., skin, hair, and/or nails), and the use of such materials selected by such methods (e.g., preparation of cosmetic compositions). The methods can also be used to generate data that can be used to support marketing claims and advertising claims, and to provide irritation and/or safety information. The methods can be used as an element of a method of doing business.

Abstract: Personal care compositions comprising an active component, use of such compositions, and methods of marketing such compositions. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.

Abstract: Personal care compositions comprising a PPARG antagonist, use of such compositions, and methods of marketing such compositions. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.

Abstract: Personal care compositions comprising a dipeptide and methods of using such compositions to treat the condition of keratinous tissue. The C terminal amino acid of said dipeptide is threonine. The personal care composition can be applied topically, ingested orally, injected, or used as part of a combined treatment regimen.

Abstract: Skin care compositions containing dehydroacetic acid, its isomers, salts, and derivatives thereof; at least two skin care actives selected from sugar amines, vitamin B3 compounds, phytosterols, salicylic acid compounds, hexamidines, dialkanoyl hydroxyproline compounds, flavonoids, n-acyl amino acid compounds, and their derivatives, and combinations thereof; and a dermatologically acceptable carrier for the dehydroacetic acid and the skin care actives. The invention further relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of the skin care composition of the invention.

Abstract: A technique for in vitro testing of ocular and dermal irritants is disclosed. The process involves the topical application of liquid, solid granular or gel-like materials (e.g. cosmetics) to a cell culture and then evaluating the cytotoxicity of the material. Cell cultures of human skin without a stratum corneum and having a histologic similarity to the eye are used. Irritation is evaluated by measuring cell viability using MTT assay (based on the reduction of a tetrazolium dye by functional mitochondria), or release of LDH or PGE.sub.2. A unique method of applying test materials which are not water soluble is described.